Anakinra use while Breastfeeding
Drugs containing Anakinra: Kineret
Anakinra Levels and Effects while Breastfeeding
Summary of Use during Lactation
Anainra is the pharmaceutical name for recombinant human interleukin-1 receptor antagonist (IL-1Ra). IL-1Ra is a normal component of human milk where it may play a role as an anti-inflammatory agent. No data exist on the excretion of anakinra into breastmilk after exogenous administration. Several infants have been breastfed during maternal anakinra therapy with no obvious adverse effects. If anakinra is required by the mother, it is not a reason to discontinue breastfeeding.
Maternal Levels. The concentration of IL-1Ra in colostrum in normal mothers was 672 ng/L, which was higher than the plasma concentration. Mature milk levels were lower than those in colostrum. Samples collected over a period of 2 to 6 months postpartum indicated that mothers continued to excrete IL-1Ra during this time. Mothers with acute mastitis had slightly higher average levels of IL-1Ra than levels after recovery, but the median values were the same. The levels found in these mothers were the same as those of control mothers.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A woman was receiving anakinra 100 mg daily for adult-onset Still's disease during pregnancy and lactation. Her breastfed (extent not stated) infant gained wight and appeared to have normal psychomotor development during an unspecified follow-up period.
Among a cohort of 18 women with term pregnancies treated with anakinra for cryopyrin-associated periodic syndromes during pregnancy, 9 of the women breastfed their infants (extent not stated). No adverse neonatal outcomes were reported.
In an international multicenter study of mothers exposed to interleukin-1 receptor antagonists, 7 babies were breastfed (extent not stated) by mothers receiving anakinra for 3 to 40 weeks. No infections or developmental abnormalities were reported.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
1. Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795-810. PMID: 26888948
2. Buescher ES, Malinowska I. Soluble receptors and cytokine antagonists in human milk. Pediatr Res. 1996;40:839-44. PMID: 8947960
3. Buescher ES, Hair PS. Human milk anti-inflammatory component contents during acute mastitis. Cell Immunol. 2001;210:87-95. PMID: 11520075
4. Berger CT, Recher M, Steiner U, Hauser TM. A patient's wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68:1794-5. PMID: 19822718
5. Chang Z, Spong CY, Jesus AA et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014;66:3227-32. PMID: 25223501
6. Youngstein T, Hoffmann P, Lane T et al. International experience of pregnancy outcomes in auto-inflammatory syndromes treated with interleukin-1 inhibitors. Pediatr Rheumatol. 2015;13 (Suppl 1):O67. DOI: doi:10.1186/1546-0096-13-S1-O67
CAS Registry Number
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
More about anakinra
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 8 Reviews – Add your own review/rating
- Drug class: antirheumatics
Other brands: Kineret